RadNet (NASDAQ:RDNT) Downgraded by Zacks Research to Hold

Key Points

• Zacks Research downgraded RadNet from Strong Buy to Hold. Analyst views remain mixed, but MarketBeat’s consensus rating is Moderate Buy with an average price target of $90.43.
• RadNet reported quarterly EPS of $0.30, beating the $0.22 consensus, while revenue rose 22.1% year over year to $638.26 million—slightly below estimates.

RadNet (NASDAQ:RDNT - Get Free Report) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating in a research report issued on Monday, Zacks reports.

Several other equities research analysts have also recently weighed in on the company. Weiss Ratings restated a "sell (d-)" rating on shares of RadNet in a research note on Wednesday, November 4th. Raymond James Financial reiterated a "strong-buy" rating on shares of RadNet in a research note on Tuesday, September 22nd. Truist Financial boosted their price target on RadNet from $90.00 to $94.00 and gave the stock a "buy" rating in a report on Tuesday, August 11th. Barclays upped their price objective on RadNet from $65.00 to $79.00 and gave the stock an "overweight" rating in a research report on Friday, August 28th. Finally, KeyCorp raised their price objective on RadNet from $92.00 to $95.00 and gave the company an "overweight" rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $90.43.

RadNet Trading Down 0.6%

Shares of RDNT stock opened at $77.94 on Monday. The company has a current ratio of 1.49, a quick ratio of 1.48 and a debt-to-equity ratio of 0.90. The stock has a market cap of $6.13 billion, a P/E ratio of -268.76 and a beta of 1.42. The stock has a 50 day simple moving average of $72.69 and a 200 day simple moving average of $65.45. RadNet has a 1 year low of $50.82 and a 1 year high of $85.84.

RadNet (NASDAQ:RDNT - Get Free Report) last posted its quarterly earnings results on Sunday, November 8th. The medical research company reported $0.30 EPS for the quarter, beating analysts' consensus estimates of $0.22 by $0.08. The business had revenue of $638.26 million during the quarter, compared to the consensus estimate of $639.97 million. RadNet had a positive return on equity of 3.14% and a negative net margin of 0.94%. RadNet's revenue for the quarter was up 22.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.20 earnings per share. On average, research analysts predict that RadNet will post 0.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On RadNet

Hedge funds have recently modified their holdings of the company. Global Retirement Partners LLC increased its holdings in RadNet by 285.2% in the 3rd quarter. Global Retirement Partners LLC now owns 470 shares of the medical research company's stock worth $32,000 after purchasing an additional 348 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of RadNet by 60.2% during the third quarter. Farther Finance Advisors LLC now owns 596 shares of the medical research company's stock valued at $41,000 after purchasing an additional 224 shares in the last quarter. Hantz Financial Services Inc. boosted its stake in shares of RadNet by 18.8% during the third quarter. Hantz Financial Services Inc. now owns 872 shares of the medical research company's stock valued at $60,000 after purchasing an additional 138 shares in the last quarter. Parallel Advisors LLC grew its holdings in shares of RadNet by 80.0% during the first quarter. Parallel Advisors LLC now owns 1,114 shares of the medical research company's stock worth $62,000 after purchasing an additional 495 shares during the last quarter. Finally, Nykredit A S bought a new stake in shares of RadNet during the second quarter worth about $153,000. Institutional investors and hedge funds own 77.90% of the company's stock.

More RadNet News

Here are the key news stories impacting RadNet this week:

• Positive Sentiment: RadNet reported third-quarter EPS of $0.30, above the $0.22 consensus, while revenue rose 22.1% year over year. It also raised its 2026 revenue outlook to $2.5 billion–$2.6 billion; reports described this as the third consecutive quarterly guidance increase. RadNet Q3 earnings and outlook
• Positive Sentiment: The planned ONRAD acquisition would give RadNet direct access to more than 225 hospitals and expand its inpatient reach. One analysis said ONRAD’s EBITDA margins above 30% could make the deal margin-accretive. Separately, Digital Health’s year-to-date contract value reached $108 million. RadNet: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: KeyCorp raised its price target to $95 from $92 and maintained an Overweight rating, signaling analyst confidence in further upside. KeyCorp stock recommendations
• Neutral Sentiment: A short-interest report stated that short interest totaled zero shares as of November 10, despite describing it as a large increase. The reported figure and description appear inconsistent, so this is not a clear trading signal.
• Negative Sentiment: Quarterly revenue of $638.26 million came in slightly below the $639.97 million analyst estimate, and RadNet reported a negative net margin. These factors may have offset some of the otherwise strong results.

About RadNet

RadNet, Inc. operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging. The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.